Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 58,500 shares to 5 new employees on December 1, 2021. The options have an exercise price of $15.11 per share, aligning with the closing stock price on that date. Each option has a 7-year term and will vest over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement to employment under the 2021 Inducement Award Plan.
Dynavax Technologies Corporation (NASDAQ: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on November 30 at 2:40 p.m. E.T. The live audio webcast can be accessed via the company's Investors section. A replay will be available for 30 days post-event. Dynavax is known for its HEPLISAV-B® vaccine approved for hepatitis B prevention and is advancing its CpG 1018 adjuvant for various vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported strong financial results for Q3 2021, achieving total revenue of $108.3 million, driven by substantial growth in its HEPLISAV-B vaccine and CpG 1018 adjuvant. Revenue for HEPLISAV-B rose to $22.7 million, up from $11.6 million year-over-year, with market share increasing to 33.5%. CpG 1018 revenue soared to $84.3 million, up from $1.7 million in Q3 2020. Net loss widened to $28.4 million, reflecting a significant non-cash loss related to warrant liability. The company ended the quarter with $414.2 million in cash and equivalents.
On November 2, 2021, Dynavax Technologies Corporation (DVAX) announced the granting of nonstatutory stock options for 5,000 shares to a newly hired employee. The options, granted at an exercise price of $20.56 per share, equal the stock's closing price on the grant date. Each option has a 7-year term and vests over three years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan aimed at incentivizing new hires.
Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Scott Myers as a new member and Chairman of its Board of Directors, succeeding Dr. Andrew Hack. Myers brings nearly three decades of experience in the pharmaceutical and medical technology sectors. Under his leadership, Dynavax aims to enhance growth, focusing on its key products: HEPLISAV-B and CpG 1018. Dr. Hack remains on the board, providing continued guidance. This leadership change is expected to strengthen the company's strategic direction in vaccine development.
Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2021 financial results on November 4, 2021, after market close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET. Interested parties can access the webcast via the company’s investors' section. Dynavax is known for developing HEPLISAV-B, a hepatitis B vaccine, and is advancing its CpG 1018 adjuvant through research collaborations targeting vaccines for various diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 115,000 shares to a new employee, effective October 18, 2021. The options have an exercise price of $17.14, aligned with the stock's closing price on the grant date. These options have a 7-year term and vest over three years, with one-third vesting after one year and the remainder in monthly installments. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and follows their 2021 Inducement Award Plan for new hires.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive topline results from Valneva's Phase 3 trial of the inactivated COVID-19 vaccine candidate, VLA2001, which utilizes Dynavax's CpG 1018 adjuvant. The trial met co-primary endpoints, demonstrating superiority over AstraZeneca's AZD1222 in geometric mean titers of neutralization antibodies and non-inferiority in seroconversion rates among adults aged 30 and older. VLA2001 showed a favorable tolerability profile with significantly fewer adverse events compared to AZD1222. Dynavax supports Valneva's continued development of the vaccine.
Dynavax Technologies Corporation (Nasdaq: DVAX) has secured a $22 million agreement with the U.S. Department of Defense to develop a recombinant plague vaccine using its CpG 1018 adjuvant over two and a half years. This collaboration includes a planned Phase 2 clinical trial, expected to commence in 2022, to assess the vaccine's immunogenicity, safety, and tolerability for adults aged 18 to 55 years. The initiative aims to enhance vaccine effectiveness and could lead to future commercial agreements with the U.S. government.
On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company. The options are priced at $16.84 per share, equal to the stock's closing price on the grant date. They have a seven-year term, vesting over three years, with one-third vesting after one year and the remainder vesting monthly. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
